Personal information

Activities

Collapse all

Employment (1)

Leiden University Medical Center: Leiden, NL

2015-10-01 to present | Professor of Translational Genetics (Human Genetics)
Employment
Source: Self-asserted source
Annemieke Aartsma-Rus

Education and qualifications (1)

Universiteit Leiden: Leiden, Zuid-Holland, NL

2000-07-01 to 2005-02-10 | PhD (Faculty of Medicine)
Qualification
Source: Self-asserted source
Annemieke Aartsma-Rus

Professional activities (9)

American Society of Gene Therapy and Cell Therapy: Milwaukee, Wisconsin, US

2010 to present | Member
Membership
Source: Self-asserted source
Annemieke Aartsma-Rus

Oligonucleotide Therapeutics Society: San Diego, US

2009 to present
Membership
Source: Self-asserted source
Annemieke Aartsma-Rus

World Muscle Society: London, GB

2007 to present
Membership
Source: Self-asserted source
Annemieke Aartsma-Rus

Nederlandse Vereniging van Gen en Cel Therapie: Amsterdam, NL

2021-11-09 | Outstanding Achievement Award
Distinction
Source: Self-asserted source
Annemieke Aartsma-Rus

International Cotton Advisory Committee: Newcastle , GB

2021-10 | Chair (2021-2024)
Distinction
Source: Self-asserted source
Annemieke Aartsma-Rus

Ammodo : Amsterdam, NL

2021 | Ammodo Science Award
Distinction
Source: Self-asserted source
Annemieke Aartsma-Rus

European Organisation for Rare Diseases: Paris, FR

2020-02 | Eurordis black pearl award
Distinction
Source: Self-asserted source
Annemieke Aartsma-Rus

Oligonucleotide Therapeutics Society: San Diego, US

2019-01-01 | President (2019-2021)
Distinction
Source: Self-asserted source
Annemieke Aartsma-Rus

TREAT-NMD: Newcastle, GB

2012-01-01 | Executive Committe Member
Distinction
Source: Self-asserted source
Annemieke Aartsma-Rus

Funding (39)

hiPS derived neurons for research and treatment of neurodevelopmental disorders

Source: Self-asserted source
Annemieke Aartsma-Rus

SCA7 as a showcase for personalized RNA therapy development in the Netherlands

2022-01 to 2024-12 | Grant
Hersenstichting (Den Haag, NL)
Source: Self-asserted source
Annemieke Aartsma-Rus

Development of accurate gene repair therapy for Duchenne muscular dystrophy

2022 to 2024 | Grant
Prinses Beatrix Spierfonds (Den Haag, NL)
Source: Self-asserted source
Annemieke Aartsma-Rus

Ammodo: studying dystrophin transcript processing in detail

2021-11 to 2024-05 | Award
Ammodo Foundation (Amsterdam, NL)
Source: Self-asserted source
Annemieke Aartsma-Rus

Developing lipid nanoparticles for muscle specific delivery of genetic therapy tools

2021 to 2022 | Grant
Duchenne UK (Hammersmith, GB)
Source: Self-asserted source
Annemieke Aartsma-Rus

TREAT-NMD EURO-NMD Translational Summerschool

2021 to 2021 | Grant
LUMC (Leiden, NL)
Source: Self-asserted source
Annemieke Aartsma-Rus

Validation of muscle homing peptides

2020 to 2024 | Grant
Sarepta Therapeutics (MA, MA, US)
Source: Self-asserted source
Annemieke Aartsma-Rus

Local genome editing for Duchenne muscular dystrophy

2020 to 2023 | Grant
Prinses Beatrix Spierfonds (Den Haag, NL)
URL: https://www.spierfonds.nl/onderzoek/gentherapie-voor-de-ziekte-van-duchenne
Source: Self-asserted source
Annemieke Aartsma-Rus

Cardiac targeting enhanced exon skipping therapy for Duchenne

2020 to 2022 | Grant
Duchenne Parent Project (Veldhoven, NL)
Source: Self-asserted source
Annemieke Aartsma-Rus

A consortium approach to preclinical testing of food supplements in animal models

2019 to 2022 | Grant
Duchenne Parent Project (Veldhoven, NL)
Source: Self-asserted source
Annemieke Aartsma-Rus

Delivery of enhanced oligonucleotide therapeutics for Duchenne muscular dystrophy

2019 to 2021 | Grant
Muscular Dystrophy Association (IL, IL, US)
Source: Self-asserted source
Annemieke Aartsma-Rus

Studying the effect of intron removal speed on exon skippability

2019 to 2021 | Grant
Sarepta Therapeutics (MA, MA, US)
Source: Self-asserted source
Annemieke Aartsma-Rus

Natural history of mdx/dba and mdx

2018 to 2022 | Grant
Duchenne UK (Hammersmith, GB)
Source: Self-asserted source
Annemieke Aartsma-Rus

Targeted interference with muscle pathology

2018 to 2022 | Grant
Prinses Beatrix Spierfonds (Den Haag, NL)
Source: Self-asserted source
Annemieke Aartsma-Rus

Preparing for double exon skipping therapy

2017 to 2019 | Grant
Duchenne Parent Project (Veldhoven, NL)
Source: Self-asserted source
Annemieke Aartsma-Rus

Muscular Dystrophy Validation Lab

2016 to present | Grant
Duchenne Parent Project (Veldhoven, NL)
Source: Self-asserted source
Annemieke Aartsma-Rus

Ducehnne Center Netherlands

2016 to 2021 | Grant
Spieren voor Spieren (Utrecht, NL)
Source: Self-asserted source
Annemieke Aartsma-Rus

Validating a mouse model to test human specific antisense oligonucleotides

2015 to 2016 | Grant
Duchenne Parent Project (Veldhoven, NL)
Source: Self-asserted source
Annemieke Aartsma-Rus

Improving 2OMePS induced exon skipping for DMD by modified chemistry

2014 to 2015 | Grant
Duchenne Parent Project (Veldhoven, NL)
Source: Self-asserted source
Annemieke Aartsma-Rus

public private partnership collaboration (exon skipping therapy development)

2014 to 2015 | Grant
Life Sciences Holland (Den Haag, NL)
Source: Self-asserted source
Annemieke Aartsma-Rus

Aptamer-based serum biomarker profiling in DMD longitudinal samples

2014 to 2014 | Grant
Parent Project Muscular Dystrophy (NJ, NJ, US)
Source: Self-asserted source
Annemieke Aartsma-Rus

Antisense therapy for several major rare diseases

Source: Self-asserted source
Annemieke Aartsma-Rus

COST Action BM107: networking towards clinical implementation of exon skipping

2013 to 2016 | Grant
European Cooperation in Science and Technology (Brussels, BE)
URL: https://www.cost.eu/actions/BM1207/
Source: Self-asserted source
Annemieke Aartsma-Rus

RD-Neuromics

2013 to 2016 | Grant
Seventh Framework Programme (Brussels, BE)
URL: https://rd-neuromics.eu/
Part of GRANT_NUMBER:

2012-305121
Source: Self-asserted source
Annemieke Aartsma-Rus

SPLICE-EB

2013 to 2016 | Grant
E-Rare (Not Applicable, NL)
Source: Self-asserted source
Annemieke Aartsma-Rus

Identification of cyclic peptides to improve muscle and heart update of AONs

2013 to 2015 | Grant
Prinses Beatrix Spierfonds (Den Haag, NL)
Source: Self-asserted source
Annemieke Aartsma-Rus

The effect of different types of exercise in mice with low levels of dystrophin

2013 to 2015 | Grant
Duchenne Parent Project (Veldhoven, NL)
Source: Self-asserted source
Annemieke Aartsma-Rus

long term treatment effects of antisense-mediated exon skipping in Duchenne muscular dystrophy

2011 to 2013 | Grant
Duchenne Parent Project (Veldhoven, NL)
Source: Self-asserted source
Annemieke Aartsma-Rus

Aspasia

2010 to present | Award
Nederlandse Organisatie voor Wetenschappelijk Onderzoek (Den Haag, NL)
Source: Self-asserted source
Annemieke Aartsma-Rus

Dissecting the splicing process of the 2.4 Mb DMD gene by transcript deep sequencing to optimize antisense mediated exon skipping for DMD

2010 to 2014 | Grant
ZonMw (Den Haag, NL)
GRANT_NUMBER: 91710303
Source: Self-asserted source
Annemieke Aartsma-Rus

Dual treatment approaches for Duchenne muscular dystrophy

2010 to 2014 | Grant
Prinses Beatrix Spierfonds (Den Haag, NL)
Source: Self-asserted source
Annemieke Aartsma-Rus

Bio-NMD

2010 to 2012 | Grant
Seventh Framework Programme (Brussels, BE)
URL: https://cordis.europa.eu/project/id/241665/fr
Part of GRANT_NUMBER:

241665
Source: Self-asserted source
Annemieke Aartsma-Rus

Cysteine quantity correction in CADASIL

2010 to 2012 | Grant
Hersenstichting (Den Haag, NL)
Source: Self-asserted source
Annemieke Aartsma-Rus

development of an innovative minitoring technology to guie the in vivo systemic treatment efficacy of antisense-exon skipping gene-correction therapy

Source: Self-asserted source
Annemieke Aartsma-Rus

Dissecting the splicing process of the 2.4 Mb DMD gene by deep seqeuncing

2009 to 2010 | Grant
Nederlandse Organisatie voor Wetenschappelijk Onderzoek (Den Haag, NL)
Source: Self-asserted source
Annemieke Aartsma-Rus

Integrated molecular and clinical research towards a therapy for DMD

2008 to 2012 | Grant
Prinses Beatrix Spierfonds (Den Haag, NL)
Source: Self-asserted source
Annemieke Aartsma-Rus

Optimization of systemic delivery and uptake of antisense oligonucleotides and conjugates in different DMD mouse models

2008 to 2010 | Grant
Duchenne Parent Project (Veldhoven, NL)
Source: Self-asserted source
Annemieke Aartsma-Rus

Towards broad clinical and technological application of gene expression engineering by exon skipping

2007 to 2012 | Grant
IOP genomics (Den Haag, NL)
Source: Self-asserted source
Annemieke Aartsma-Rus

TREAT-NMD

2007 to 2011 | Grant
Sixth Framework Programme (Brussels, BE)
URL: http://www.treat-nmd.org
Part of GRANT_NUMBER:

LSHM-CT-2006-036825grant
Source: Self-asserted source
Annemieke Aartsma-Rus
How many people are using ORCID?